Akari Therapeutics PLC
CLA
Company Profile
Business description
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
Contact
22 Boston Wharf Road
7th Floor
BostonMA02210
USAT: +1 929 274-7510
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
12
Stocks News & Analysis
stocks
Fair value upgrade for this ASX income player
Headwinds in listed energy stocks likely to have passed
stocks
The SpaceX IPO and the Elon Musk factor
Potential investors should remember that the company’s controlling shareholder can move markets with a few words.
stocks
The ASX’s most shorted stocks in 2026
What we can and can’t learn from the top 20 most shorted ASX shares.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,683.90 | 11.50 | 0.13% |
| CAC 40 | 7,834.86 | 62.41 | 0.80% |
| DAX 40 | 22,778.98 | 216.10 | 0.96% |
| Dow JONES (US) | 45,216.14 | 49.50 | 0.11% |
| FTSE 100 | 10,226.76 | 98.80 | 0.98% |
| HKSE | 24,788.14 | 37.35 | 0.15% |
| NASDAQ | 20,794.64 | 153.72 | -0.73% |
| Nikkei 225 | 51,063.72 | 822.13 | -1.58% |
| NZX 50 Index | 12,912.11 | 163.19 | 1.28% |
| S&P 500 | 6,343.72 | 25.13 | -0.39% |
| S&P/ASX 200 | 8,481.80 | 4.60 | 0.05% |
| SSE Composite Index | 3,891.86 | 31.43 | -0.80% |